BioWorld

April 30, 2008

Second Strike on Rituxan as it Fails in Lupus Trial

Still reeling from a negative study of Rituxan in multiple sclerosis patients, Genentech Inc. and Biogen Idec Inc. reported more unfavorable data Tuesday from a Phase II/III study of the drug in lupus patients. (BioWorld Today) Read More

Constellation's Series A Adds $32M for Epigenetics Platform

Paper Stirs Science Debate Over Tumor Angiogenesis

Panel Debates Knotty Challenges Facing Follow-on Biologics

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...